D.E. Shaw & Co
EDIT icon

D.E. Shaw & Co’s Editas Medicine EDIT Stock Holding History

D.E. Shaw & Co’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,000
Closed -$473K – 5267
2022
Q2 		$473K Sell
40,000
-184,600
-82% -$2.47M ﹤0.01% 4119
2022
Q1 		$4.27M Buy
224,600
+105,400
+88% +$1.96M ﹤0.01% 2503
2021
Q4 		$3.17M Buy
119,200
+39,200
+49% +$1.35M ﹤0.01% 2900
2021
Q3 		$3.29M Sell
80,000
-70,000
-47% -$3.84M ﹤0.01% 2539
2021
Q2 		$8.5M Buy
150,000
+90,000
+150% +$3.32M 0.01% 1635
2021
Q1 		$2.52M Buy
+60,000
New +$3.42M ﹤0.01% 2393

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

D.E. Shaw & Co's EDIT Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Editas Medicine (EDIT) stake by 2.2% in Q2 2026, selling an estimated $125K and leaving 1,901,002 shares worth $6.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

D.E. Shaw & Co first reported a position in EDIT in Q4 2016 and has held it in 39 quarters since. The position peaked at $98.8M in Q4 2020. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • D.E. Shaw & Co held 1,901,002 shares of Editas Medicine worth $6.16M as of Q2 2026.
  • D.E. Shaw & Co sold 42,891 Editas Medicine shares in Q2 2026, an estimated $125K.
  • Editas Medicine made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2235 holding.
  • D.E. Shaw & Co first reported a position in Editas Medicine in Q4 2016 and has held it in 39 quarters since.
  • D.E. Shaw & Co's Editas Medicine position peaked at $98.8M in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.